Inhalable formulation for treating pulmonary conditions and controls nitric oxide levels, acute treatment of hypoxia due to cystic fibrosis and pneumonitis, treating bacterial infections and tuberculosis, treating sepsis of pulmonary origin, comprises a methylene blue and/or optionally excipients
	IYER E K; NEGI A S; VIDWANS K
	2023-09-22
专利权人	IYER E K (IYER-Individual) ; NEGI A S (NEGI-Individual) ; VIDWANS K (VIDW-Individual)
申请日期	2023-09-22
专利号	IN202321063942-A
成果简介	NOVELTY - Inhalable formulation comprises a methylene blue having a particle size 90% of particles are less than 8 µm, 50% of particle size are less than 5 µm and 10% of particles are less than 3 µm, and/or (ii) optionally excipients, where the administration of the formulation through a dry powder inhaler, a metered dose inhaler or a soft mist inhaler. USE - Inhalable formulation used for treating pulmonary conditions and controls nitric oxide levels, for acute treatment of hypoxia due to cystic fibrosis and pneumonitis, for treating bacterial infections, including tuberculosis, for treating sepsis of pulmonary origin and/or aspiration pneumonia, prevention of cytokine storm, as an antidote to toxic gases and cyanide comprising chemicals (such as pesticides) upon exposure of the airways, as rescue medication in persons, who are exposed to smoke or carbon monoxide. No biological data given. ADVANTAGE - The inhalable formulation enables direct delivery to the lungs also acts as an immediate relief and/or treatment measure in cases of exposure of the lungs to toxics gases, smoke, pesticides, preventing or reducing tissue hypoxia, and also reducing the severity of inflammation of the lung tissue, use of a suitable dose of methylene blue via inhalation route for localized delivery to the site of action, optionally at a reduced dose, achieves a therapeutic effect use of the engineered particle size of methylene blue for producing a dry powder, reduces systemic side effects of methylene blue and direct delivery to the lungs allows significant dose reduction, which reduces the chances of increase in systemic vascular resistance.
IPC 分类号	A61K-031/00 ; A61K-031/167 ; A61K-031/4704 ; A61K-031/485 ; A61K-045/06 ; A61K-009/00 ; A61K-009/12 ; A61K-009/72
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/20292
专题	中国科学院新疆生态与地理研究所
作者单位	1.IYER E K (IYER-Individual) 2.NEGI A S (NEGI-Individual) 3.VIDWANS K (VIDW-Individual)
推荐引用方式 GB/T 7714	IYER E K,NEGI A S,VIDWANS K. Inhalable formulation for treating pulmonary conditions and controls nitric oxide levels, acute treatment of hypoxia due to cystic fibrosis and pneumonitis, treating bacterial infections and tuberculosis, treating sepsis of pulmonary origin, comprises a methylene blue and/or optionally excipients. IN202321063942-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。